Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 40 Colorectal Neoplasms 25 Colonic Neoplasms 10 Brain Neoplasms 8 Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Neoplasm Metastasis 6 Rectal Neoplasms 5 Skin Neoplasms 4 Lung Neoplasms 3 Gastrointestinal Neoplasms 3 Pancreatic Neoplasms 2 Digestive System Neoplasms 2 Thyroid Neoplasms 1 Solid Tumors Harboring a BRAF V600 Mutation 1 Solid Tumors 1 Solid Tumor 1 Skin Diseases 1 Recurrence 1 Rectal Diseases 1 Neurofibromatosis 1 1 Multiple Myeloma 1 Lymphatic Metastasis 1 Leukemia, Hairy Cell 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1

Interventions

pembrolizumab 14 Injections 13 Paclitaxel 10 Nivolumab 10 Docetaxel 9 Cisplatin 9 Capecitabine 9 Bevacizumab 8 toripalimab 7 senaparib 7 Fluorodeoxyglucose F18 7 Cyclophosphamide 7 tislelizumab 6 atezolizumab 6 Irinotecan 6 Fluorouracil 6 Gemcitabine 5 fludarabine 4 apatinib 4 Oxaliplatin 4 Leucovorin 4 Ipilimumab 4 spartalizumab 3 pertuzumab 3 olaparib 3 camrelizumab 3 Rifampin 3 Radiosurgery 3 Midazolam 3 Itraconazole 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor × encorafenib × Clear all

NCT03839342 2025-02-03

BEAVER

University Health Network, Toronto

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡